TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
PHILADELPHIA, Jan. 26, 2016 -- Medgenics, Inc. (NYSE MKT:MDGN), today announced that members of its management team will participate in the 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day on Tuesday, February 2, 2016 in New York, NY.
About Medgenics, Inc.
Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. For more information, visit the Company's website at www.medgenics.com.
Contacts: Medgenics, Inc. Brian Piper [email protected]
